2013 Epilepsy Extraction Research and Development 
Cannabis Law Report
JULY 12, 2019
By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC.
The Cannigma
JUNE 15, 2021
Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 8, 2021
And all thanks to the latest medical research. If earlier cannabis was a taboo subject due to its psychedelic properties, then with the development of technologies that allow the extraction of pure cannabidiol, the situation has changed radically. The development of new varieties and genetic research.
Alchimia
JUNE 20, 2016
A study published in February 2015 in the Pharmacology & Pharmacy journal showed that a CBD-rich extract from cannabis plants is much more efficient than CBD used in its pure form , mainly due the presence of other cannabinoids, terpenes and other molecules that greatly increase the dosage/efficiency ratio of CBD.
Cannabis Law Report
FEBRUARY 1, 2020
While much of this development has been concentrated in Europe and the US, several nations in Asia-Pacific have also recently shifted towards greater tolerance. Medical Use & Cannabis Research. in 2013 to 14.5% Medical Use & Cannabis Research. Unfortunately, such costs can quickly become prohibitive.
Healer
JANUARY 17, 2022
More recently, breeders have developed varieties of cannabis that lack the enzymes responsible for converting CBGA into the other cannabinoids, resulting in fully mature flowers dominant in CBGA and low in THC and other cannabinoids. As research grows we’ll learn more about the therapeutic potential of CBG in infectious conditions.
Healer
JANUARY 17, 2022
More recently, breeders have developed varieties of cannabis that lack the enzymes responsible for converting CBGA into the other cannabinoids, resulting in fully mature flowers dominant in CBGA and low in THC and other cannabinoids. As research grows we’ll learn more about the therapeutic potential of CBG in infectious conditions.
Expert insights. Personalized for you.
73 
Let's personalize your content